Difference between revisions of "Aldesleukin (Proleukin)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
Line 1: Line 1:
Also known as interleukin-2, IL-2, or Macrolin.
 
 
 
==General information==
 
==General information==
Class/mechanism: Recombinant interleukin-2 which activates the immune system.  Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.<ref name="insert">[http://www.proleukin.com/assets/proleukin.pdf Aldesleukin (Proleukin) package insert]</ref><ref>[[Media:Aldesleukin.pdf | Aldesleukin (Proleukin) package insert (locally hosted backup)]]</ref><ref>[http://www.proleukin.com/ Proleukin manufacturer's website]</ref>
+
Class/mechanism: Recombinant interleukin-2 which activates the immune system.  Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.<ref name="insert">[https://www.proleukin.com/downloads/proleukin-pi.pdf Aldesleukin (Proleukin) package insert]</ref><ref>[[Media:Aldesleukin.pdf | Aldesleukin (Proleukin) package insert (locally hosted backup)]]</ref><ref>[http://www.proleukin.com/ Proleukin manufacturer's website]</ref>
 
<br>Route: IV
 
<br>Route: IV
 
<br>Extravasation: no information
 
<br>Extravasation: no information
Line 19: Line 17:
 
==History of changes in FDA indication==
 
==History of changes in FDA indication==
 
* 5/5/1992: Initial FDA approval
 
* 5/5/1992: Initial FDA approval
 +
 +
==Also known as==
 +
Interleukin-2, IL-2, or Macrolin.
  
 
==References==
 
==References==

Revision as of 01:12, 21 May 2017

General information

Class/mechanism: Recombinant interleukin-2 which activates the immune system. Aldesleukin encourages growth of IL-2 dependent cells, triggers natural killer (NK) and lymphokine-activated killer (LAK) cell activity, induces production of interferon gamma, and increases lymphocyte cytotoxicity.[1][2][3]
Route: IV
Extravasation: no information

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

  • 5/5/1992: Initial FDA approval

Also known as

Interleukin-2, IL-2, or Macrolin.

References